quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:15:53·266d
SECFiling
Zynex Inc. logo

SEC Form 10-Q filed by Zynex Inc.

ZYXI· Zynex Inc.
Health Care
Original source

Companies

  • ZYXI
    Zynex Inc.
    Health Care

Recent analyst ratings

  • Aug 1UpdateLadenburg Thalmann$3.70
  • Aug 1UpdateH.C. Wainwright-
  • Mar 12UpdateRBC Capital Mkts$5.50
  • Mar 12UpdateLadenburg Thalmann-
  • Oct 16UpdateRBC Capital Mkts$13.00
  • Jan 6UpdatePiper Sandler$18.00

Related

  • SEC126d
    Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
  • SEC128d
    Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR128d
    Zynex Financial Restructuring Puts Company on Path to Long-Term Success
  • INSIDER154d
    SEC Form 3 filed by new insider Aronzon Paul
  • SEC157d
    SEC Form 10-Q filed by Zynex Inc.
  • SEC157d
    Zynex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR157d
    Zynex Reports Third Quarter 2025 Financial Results
  • PR160d
    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022